These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 27866064)

  • 21. Drugs for type 2 diabetes.
    Treat Guidel Med Lett; 2011 Aug; 9(108):47-54. PubMed ID: 21778966
    [No Abstract]   [Full Text] [Related]  

  • 22. Diabetes: Time for reconciliation between cardiologists and diabetologists.
    Scheen AJ
    Nat Rev Cardiol; 2016 Sep; 13(9):509-10. PubMed ID: 27411401
    [No Abstract]   [Full Text] [Related]  

  • 23. Incretin-based therapies for type 2 diabetes mellitus: New therapeutic mechanisms.
    Kennedy L
    Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S2-3. PubMed ID: 19952299
    [No Abstract]   [Full Text] [Related]  

  • 24. Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects.
    Drab SR
    Pharmacotherapy; 2010 Jun; 30(6):609-24. PubMed ID: 20500049
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novo Nordisk replies to BMJ investigation on incretins and pancreatic damage.
    Moses A
    BMJ; 2013 Jul; 347():f4386. PubMed ID: 23842435
    [No Abstract]   [Full Text] [Related]  

  • 26. The Yin and the Yang of CV risks in patients with diabetes.
    Dangi-Garimella S
    Am J Manag Care; 2014 May; 20(8 Spec No.):E6. PubMed ID: 25617925
    [No Abstract]   [Full Text] [Related]  

  • 27. Tapping incretin-based therapy for type 2 diabetes.
    Appel SJ
    Nursing; 2011 Mar; 41(3):49-51. PubMed ID: 21326056
    [No Abstract]   [Full Text] [Related]  

  • 28. GLP-1 receptor agonists: effects on cardiovascular risk reduction.
    Lorber D
    Cardiovasc Ther; 2013 Aug; 31(4):238-49. PubMed ID: 23865382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and economic implications of incretin-based therapies.
    Briggs GC
    Endocrinol Metab Clin North Am; 2007 Dec; 36 Suppl 2 Incretin():18-26. PubMed ID: 18405145
    [No Abstract]   [Full Text] [Related]  

  • 30. Incretin-based pharmacotherapy and risk of adverse pancreatic events in the ethnic Chinese with diabetes mellitus: A population-based study in Taiwan.
    Tseng CM; Liao WC; Chang CY; Lee CT; Tseng CH; Hsu YC; Lin JT
    Pancreatology; 2017; 17(1):76-82. PubMed ID: 27743712
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incretin therapies and risk of hospital admission for acute pancreatitis in an unselected population of European patients with type 2 diabetes: a case-control study.
    Giorda CB; Picariello R; Nada E; Tartaglino B; Marafetti L; Costa G; Gnavi R
    Lancet Diabetes Endocrinol; 2014 Feb; 2(2):111-5. PubMed ID: 24622714
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cardiovascular safety of incretin-based antidiabetic treatment - results of completed clinical trials].
    Jermendy G
    Orv Hetil; 2016 Apr; 157(16):603-10. PubMed ID: 27063427
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diabetes Mellitus and Its Cardiovascular Complications: New Insights into an Old Disease.
    Sardu C; De Lucia C; Wallner M; Santulli G
    J Diabetes Res; 2019; 2019():1905194. PubMed ID: 31236416
    [No Abstract]   [Full Text] [Related]  

  • 34. An updated review on cancer risk associated with incretin mimetics and enhancers.
    Tseng CH; Lee KY; Tseng FH
    J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2015; 33(1):67-124. PubMed ID: 25803196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incretin-based therapy: Is the risk of pancreatitis driven by cardiovascular disease?
    Sohani ZN; Li L; Sun X
    Diabetes Res Clin Pract; 2016 Jul; 117():28-31. PubMed ID: 27329019
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Innovations in the treatment of type 2 diabetes mellitus: use of incretins].
    Dedov II; Shestakova MV; Sukhareva OIu
    Ter Arkh; 2010; 82(10):5-10. PubMed ID: 21341455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes.
    St Onge EL; Miller SA
    Expert Opin Biol Ther; 2010 May; 10(5):801-6. PubMed ID: 20367248
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Incretin-based antidiabetic treatment and diseases of the pancreas (pancreatitis, pancreas carcinoma)].
    Jermendy G
    Orv Hetil; 2016 Apr; 157(14):523-8. PubMed ID: 27017851
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors.
    Mathieu C; Bollaerts K
    Int J Clin Pract Suppl; 2007 Aug; (154):29-37. PubMed ID: 17593275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incretin therapy for type 2 diabetes mellitus.
    Klonoff DC
    Adv Ther; 2010 Dec; 27(12):881-94. PubMed ID: 20978879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.